Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI4619

Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice.

H Yoneyama, A Harada, T Imai, M Baba, O Yoshie, Y Zhang, H Higashi, M Murai, H Asakura, and K Matsushima

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Yoneyama, H. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Harada, A. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Imai, T. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Baba, M. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Yoshie, O. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Zhang, Y. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Higashi, H. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Murai, M. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Asakura, H. in: JCI | PubMed | Google Scholar

Department of Molecular Preventive Medicine, School of Medicine, and CREST, The University of Tokyo, Tokyo 113, Japan.

Find articles by Matsushima, K. in: JCI | PubMed | Google Scholar

Published December 1, 1998 - More info

Published in Volume 102, Issue 11 on December 1, 1998
J Clin Invest. 1998;102(11):1933–1941. https://doi.org/10.1172/JCI4619.
© 1998 The American Society for Clinical Investigation
Published December 1, 1998 - Version history
View PDF
Abstract

Thymus and activation-regulated chemokine (TARC) is a recently identified lymphocyte-directed CC chemokine which specifically chemoattracts T helper type 2 CD4(+) T cells in human. To establish the pathophysiological roles of TARC in vivo, we investigated whether a monoclonal antibody (mAb) against TARC could inhibit the induction of hepatic lesions in murine model using Propionibacterium acnes and lipopolysaccharide (LPS). P. acnes-induced intrahepatic granuloma formation in the priming phase is essential to the subsequent liver injury elicited by a low dose of LPS. The priming phase appears to be dominated by Th1 type immune responses determined by the profile of chemokine and chemokine receptor expression. TARC was selectively produced by granuloma-forming cells, and CC chemokine receptor 4 (CCR4)-expressing CD4(+) T cells migrated into the liver after LPS administration. In vivo injection of anti-TARC mAb just before LPS administration protected the mice from acute lethal liver damage, which was accompanied by a significant reduction of both CCR4 mRNA expression and IL-4 production by liver-infiltrating CD4(+) T cells. Moreover, both TNF-alpha and Fas ligand expressions in the liver were decreased by anti-TARC treatment. These results suggest that recruitment of IL-4-producing CCR4(+) CD4(+) T cells by granuloma-derived TARC into the liver parenchyma may be a key cause of massive liver injury after systemic LPS administration.

Version history
  • Version 1 (December 1, 1998): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts